[1] |
LI Wenpeng, LIU Mingyu, CAO Ying, ZHOU Huziwei, WANG Shengfeng.
Supervision status and research progress of global abuse of opioids
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 513-518.
|
[2] |
CAO Ying, ZHOU Huziwei, ZHU Lan, WANG Shengfeng.
Management of compound glycyrrhiza oral solution and recommendations
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 529-534.
|
[3] |
YU Jing, PALATI Reheman, ZHAO Ting, FENG Jirong, SUN Yan, HE Lei.
Correlation of the efficacy, safety and plasma concentration of lacosamide in the treatment of children with epilepsy under 4 years of age
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 559-562.
|
[4] |
WANG Shubo, JIAO Tingting, DONG Hongliang, WANG Bailing, LI Hui.
A model for prediction of risk factors of acute kidney injury induced by voriconazole for injection based on real-world data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 567-571.
|
[5] |
SU Xiaohan, ZENG Jiao, LI Xue, LIU Lixin, HOU Lingmi, LI Jinsui.
Adverse events of abemaciclib in breast cancer patients based on US FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 580-586.
|
[6] |
LIU Jie, ZHANG Jianmin, ZHANG Xiaomeng, LIU Fang, SONG Yuan, ZHONG Xuli.
Management of risks to pediatric medications based on drug instructions of Chinese patent medicines in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 422-427.
|
[7] |
YANG Bo, WANG Mengjiao, HU Lili, WANG Laicheng, LI Qian, KONG Feifei, LYU Dongmei, SHEN Jiani.
Safety assessment and risk factor analysis of PD-1 immunotherapy in a cohort of 385 patients
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 447-450.
|
[8] |
LI haiyan, YANG Zhongxu, LIU Yuekun, WANG Lihong.
Pharmaceutical care of serious adverse reactions due to methotrexate treatment of ectopic pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 454-456.
|
[9] |
LI Shaoqiang, KONG Xudong, LI Pengmei.
One case of hyponatremia caused by omeprazole sodium for injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 461-463.
|
[10] |
GU Xiaotong, SUN Xuelin, ZHENG Li.
Pharmacological effect and clinical evaluation of rezafungin in treating candidemia and invasive candidiasis
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 469-472.
|
[11] |
WU Shiqi, YAN Suying, ZHANG Qingxia.
Research progress in pharmacokinetic interactions of edoxaban
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 473-480.
|
[12] |
ZHANG Chenxue, PEI Yusheng, CAI Tong.
Research progress in bacterial endotoxin test methods for insoluble raw materials, excipients and preparations
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 273-279.
|
[13] |
LIU Yi, QIN Ling, GUO Xianhui, CHEN Hua, PEI Yusheng.
Applications of TGA and DSC in pharmaceutical analysis
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 283-289.
|
[14] |
ZHANG Xiaoming, LYU Ping, HU Xinyue, DING Xiaoli, LI Jing, LIANG Chenggang.
Detection of single-chain precursor residues in insulin glargine by ELISA
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 290-294.
|
[15] |
HUANG Huanjun, MAI Jiaheng, ZHANG Yunhui, GUO Chenchen, LIANG Weiting.
Adverse drug reaction induced by antineoplastic drugs in a cancer hospital: an analysis of 613 cases
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 324-328.
|